Drug details

Vemlidy Tablets (tenofovir alafenamide)

type of Hepatitis B, NRTIs

Vemlidy (tenofovir alafenamide) is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease.

The drug is often used to treat Liver disease .

This drug may have the following side effects:
  • hives,
  • difficulty breathing,
  • swelling of your face, lips, tongue, or throat,
  • nausea,
  • loss of appetite,
  • dark urine,
  • vomiting,
  • confusion,
  • stomach pain,
  • little or no urination,
  • mood changes,
  • drowsiness,
  • anxiety,
  • depression,
  • severe dizziness
  • yellowing of the eyes or skin (jaundice),
  • unusual thirst,
  • unusual weakness, and
  • deep or rapid breathing,
The following drugs are related to Vemlidy Tablets, either as a replacement or used together:
  • Hepsera (adefovir dipivoxil)
  • Alphanate (antihemophilic factor)
  • Baygam (immune globulin)
  • Comvax (haemophilus b conjugate and hepatitis b vaccine)
  • Daklinza (daclatasvir tablets)
  • Dovato (dolutegravir and lamivudine tablets)
  • Egrifta SV (tesamorelin for injection)
  • Emtriva (emtricitabine)
  • Epivir-HBV (lamivudine tablets and oral solution)
  • gamaSTAN (immune globulin (human) for injection)
  • Havrix (hepatitis a vaccine, inactivated)
  • Twinrix (hepatitis a inactivated & hepatitis b (recombinant) vaccine)
  • Sunlenca (lenacapavir tablets and injection)
  • Rebetol (ribavirin)